Advances in ALK Targeted Therapy for Neuroblastoma
- *Corresponding Author:
- Sylvain Baruchel
Innovative Therapeutic Trials Office
Dept. of Pediatrics and Research Institute
The Hospital for Sick Children, 555 University Avenue
Toronto, Ontario, Canada M5G 1X8
E-mail: [email protected]
Received date: July 27, 2017; Accepted date: July 27, 2017; Published date: August 03, 2017
Citation: Zhang L, Baruchel S (2017) Advances in ALK Targeted Therapy for Neuroblastoma. J Oncol Transl Res 3:114. doi:10.4172/2476-2261.1000114
Copyright: © 2017 Zhang L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and prognostic alterations, to stratify the risk of recurrence or progression, and to develop optimal monitoring and treatment strategies in this malignancy.